SPRC ▼ -2.6% - SciSparc Ltd. $SPRC - SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI?210 Autism Clinical Trial SciSparc fell 2.6% today despite its subsidiary NeuroThera Labs reporting significant enrollment progress in the SCI-210 clinical trial for autism. The market's muted or negative reaction suggests investors may be focusing on near-term capital needs, trial execution risks, or other concerns that outweighed the positive enrollment update. 31-AUG-2026 04:03 PM ET